doac - search results

If you're not happy with the results, please do another search

HRS 2021: DOACs reduce risk of stroke in patients undergoing left ventricular RFA

Use of direct oral anticoagulants (DOACs) in patients undergoing ventricular tachycardia radio frequency ablation (RFA) is associated with a reduced risk of transient ischaemic...

DOACs show better safety and effectiveness versus warfarin in patients with valvular AF

Patients with valvular atrial fibrillation (AF) who were new users of direct oral anticoagulants (DOACs) were at lower risk for ischaemic stroke or systemic...
Cardiac Rhythm news for specialists

ESC 2019: Study suggests increased use of DOACs in AF leads to lower healthcare...

A four-year Italian study of oral anticoagulant (OAC) use in patients with atrial fibrillation (AF) has shown that as prescription rates increased healthcare costs...

Analysis of the BRUISE CONTROL 1 and 2 trials shows no difference in clinically...

By Hannah Woolley In a multivariate analysis including both BRUISE CONTROL 1 and BRUISE CONTROL 2 patients and adjusted for antiplatelet use, there was no...

ESC 2022: Risk score predicts mortality for AF patients after TAVI

Researchers have developed a risk score to predict mortality for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation...

TVT 2022: DAPT after Watchman FLX LAAO is comparable to currently approved regimens

Dual antiplatelet therapy (DAPT) after left atrial appendage occlusion (LAAO) using the Watchman FLX (Boston Scientific) device was comparable in terms of rates of...
Kazunori Toyoda

Alternative timing method for direct oral anticoagulants following ischaemic stroke with atrial fibrillation deemed...

A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...

ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse events after TAVI

Edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation (TAVI), new...

Anticoagulants fail to improve survival from COVID-19, Swedish study finds

The use of direct oral anticoagulants (DOACs) did not reduce the rate of hospitalisation, intensive care admission or fatality due to COVID-19, according to...

AHA 2020: Rivaroxaban may be comparable to warfarin for bioprosthetic mitral valves, AF

The primary results from the RIVER Trial—Rivaroxaban for Valvular Heart disease and Atrial Fibrillation—show that rivaroxaban is comparable to warfarin for patients with bioprosthetic...
Cardiac Rhythm news for specialists

ESC 2020 Congress: Daiichi Sankyo announces results from ETNA-AF studies

Daiichi Sankyo Europe has announced one-year results of four sub-analyses from the European and global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients...

Low rates of bleeding and mortality reported in one-year results of ETNA-AF trial

Daiichi Sankyo Europe has announced the publication of one-year follow-up results from the ongoing ETNA-AF-Europe (Edoxaban Treatment in routiNe clinical prActice for patients with...

Algorithms can identify rate of OAC prescription for AF in emergency departments

Researchers have derived several algorithms to identify emergency department (ED) oral anticoagulant prescriptions for patients with atrial fibrillation (AF) in a large health dataset....

Cardiac Rhythm News Issue 46 – October 2019

Highlights: ESC guidelines on supraventricular tachycardias underline the pivotal role of catheter ablation therapy Study suggests increased use of DOACs in AF leads to...

President of Venice Arrhythmias discusses current challenges in atrial fibrillation management

Antonio Raviele (Venice, Italy), the president of Venice Arrhythmias 2019 (3–5 October; Venice, Italy), talks to BLearning Cardio about some of the current challenges in atrial fibrillation (AF)...

Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for...

According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...

Point-of-care testing of coagulation in patients treated with edoxaban

The first systematic evaluation of coagulation point-of-care testing in edoxaban treated patients has been carried out. The results were presented by Florian Härtig, University...

Brain MRI scans can inform the choice between OACs and LAA closure for non-valvular...

M Edip Gurol is a stroke neurologist with particular expertise in the care of patients at high risk for ischaemic (blockage type) strokes and...

Four out of 10 AF patients may not receive necessary stroke-prevention medication

Many patients with an irregular heartbeat, known as atrial fibrillation, are not receiving recommended blood thinning medication they need to prevent strokes, according to...

Athena Poppas

Eric Prystowsky

Eric N Prystowsky

Pedro Brugada